MAP Pharmaceuticals News
Most Popular MAP Pharmaceuticals Story
MAP touts inhalable migraine med data
Shares of MAP Pharmaceuticals soared this morning on news that the company's inhalable migraine therapy Levadex (MAP0004) met all four primary endpoints in a Phase III study. Levadex achieved Read more...
Latest Headlines
- January 31, 2011
- July 9, 2009
- May 26, 2009
- February 24, 2009
- December 22, 2008
- December 19, 2008
- September 21, 2007
- January 25, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
